Loading...
Loading...
EXEL| Name | Value |
|---|---|
| Revenues | 471.9M |
| Cost of Revenue | 18.8M |
| Gross Profit | 453.1M |
| Operating Expense | 470.7M |
| Operating I/L | -17.6M |
| Other Income/Expense | 23.4M |
| Interest Income | 23.1M |
| Pretax | 5.8M |
| Income Tax Expense | 4.8M |
| Net Income/Loss | 1.0M |
Exelixis, Inc. is an oncology-focused biotechnology company in the United States. It specializes in discovering, developing, and commercializing new medicines for cancer treatment. The company's products include CABOMETYX and COMETRIQ, derived from cabozantinib, targeting multiple tyrosine kinases. Additionally, it offers COTELLIC for advanced melanoma and MINNEBRO for hypertension in Japan. Exelixis is also developing XL092, XB002, and XL102 for various cancer treatments. The company has research collaborations and license agreements with several pharmaceutical companies. Its revenue is generated through the sale of its cancer treatment products and through partnerships and collaborations with other pharmaceutical companies.
